Healthcare Economist August 20, 2024
An interesting study from Miquel Serra-Burriel et al. (2024) examines the impact of genericization on drug prices across 8 high-income countries (Australia, Canada, France, Germany, Japan, Switzerland, UK, and US). The authors used 2011-2020 IQVIA MIDAS data across 505 novel originator drugs. They found that:
Price decreases were statistically significant over the 8 years after patent expiration, with the fastest price declines observed in the US: 32% (95% CI, 24%-39%) in year 1...
Today's Sponsors
Today's Sponsor